Neurology has become one of the fastest-evolving areas in clinical research. Advances in genetics, biomarkers, and trial design are unlocking new possibilities across epilepsy, Alzheimer’s, Parkinson’s, and rare neurological diseases. This article presents a data-driven overview of the neurology study landscape in 2026, covering indication-level market segmentation, key trends, and insights from the latest industry reports.
The global neurology clinical trials market is entering a phase of robust growth driven by an aging population, rising prevalence of neurodegenerative diseases, and a surge in innovation. According to the Future Market Insights report, the market is estimated to be valued at USD 6.8 billion in 2025 and is projected to reach USD 12.5 billion by 2035, registering a CAGR of 6.3% over the forecast period.
Additional insight from the FMI report, that the leading segment by trial phase in 2025 is Phase I, accounting for 38.6% of total market revenue, driven by an increasing number of novel drug entities entering the pipeline for neurological conditions. Early-phase trials are critical for assessing safety, tolerability, and pharmacokinetics in the complex CNS landscape.
The distribution of trials across neurology indications is uneven, dictated by unmet medical need, funding availability, and scientific tractability. According to FMI’s 2025 segmentation by indication:
Epilepsy holds the leading position by revenue share at 33.8%, benefiting from clearly defined clinical endpoints, robust patient registries, and a persistent unmet need in drug-resistant epilepsy. Alzheimer’s disease, while second in volume, represents the highest-value segment; its pipeline has expanded to 182 active trials as of 2025, a 9% increase from 2024, with 70% of these investigating mechanisms beyond amyloid. Parkinson’s disease continues to attract substantial investment, reflected in high-value collaborations such as Novartis’s partnership with UCB (USD 150 million) and Biogen’s deal with Alectos (up to USD 630 million). Stroke accounts for approximately 15% of the market, driven by its high contribution to global disability-adjusted life years (DALYs). Multiple sclerosis represents a more mature segment, where the focus is shifting from immunomodulation toward neuroprotection and remyelination. The remaining indications, including Huntington’s disease, ALS, and traumatic brain injury, are characterized by orphan drug activity and gene therapy development.
According to data published in the Lancet, total disability-adjusted life years (DALYs) from non-communicable neurological disorders, including stroke, Alzheimer’s disease, dementia, Parkinson’s disease, and headache disorders, increased significantly in India, contributing to 82.8% of the overall neurological burden in 2020.
Several key trends are reshaping neurology clinical trials in 2026.
– The shift to interventional study designs remains dominant: according to the FMI report, the interventional segment is expected to contribute 47.2% of total market revenue by 2025, as interventional trials allow direct assessment of drug efficacy and safety with enhanced regulatory clarity.
– The rise of genetic medicine and high-value collaborations is accelerating, highlighted by Novartis’s Zolgensma data for SMA, Biogen’s partnership with Alectos for a Parkinson’s small molecule therapy (up to USD 630 million in milestone payments), and GSK’s collaboration with Alector on progranulin-elevating antibodies for dementia and Alzheimer’s.
– Biomarkers and precision enrollment are becoming mandatory, with advanced biomarkers now strengthening Phase I first-in-human studies conducted in specialized research centers.
– Decentralized and hybrid trials are overcoming patient recruitment challenges, as technological tools such as wearable devices and real-time data capture systems improve trial efficiency and monitoring, enhancing the feasibility of conducting interventional studies even in decentralized settings.
– Model-Informed Drug Development (MIDD) is another critical trend – the FDA has partnered with the Critical Path Institute to develop clinical trial simulation tools for Alzheimer’s, Parkinson’s, and Duchenne muscular dystrophy, helping optimize trial design, distinguish symptomatic from disease-modifying effects, and address ethical concerns by allowing control group participants to switch to active treatment.
Despite the optimism, significant hurdles remain. According to the Tufts Center for the Study of Drug Development, as cited in the Applied clinical Trials, CNS drugs take 18% more time to develop when compared to other drugs, and only 6% of CNS drugs are finally approved out of clinical testing – statistics discouraging enough that some pharmaceutical companies are choosing not to invest in neurological clinical trials altogether. The high cost of clinical trials coupled with high failure rates drives some players to leave the market entirely. Additionally, the difficulty of diagnosis poses a major barrier: CNS disorders are studied based on symptoms and signs, with varied underlying causes across patients within the same diagnostic category, making patient identification and stratification exceptionally challenging. Furthermore, animal models of CNS disorders have not shown effective predictive validity and reproducibility, consistently failing to recreate the varied and complex nature of human neurological conditions. These factors collectively create a high-risk environment that demands significant upfront investment and carries an elevated probability of late-stage failure.
The next decade will likely be defined by platform technologies rather than single drugs.
The neurology clinical trials market has transitioned from a high-risk gamble to a strategic necessity for major pharmaceutical players. With a projected market value exceeding $12 billion by 2035, the sector is defined by scientific sophistication — using genetics, biomarkers, and AI to de-risk development. While epilepsy and MS remain pillars of the market, the “gold rush” is currently centered on Alzheimer’s and the frontier of genetic therapy for rare neurodegenerative diseases.
With decades of collective expertise in complex CNS trials, Palleos stands as a trusted clinical trial CRO Europe, offering full-service support across epilepsy, Alzheimer’s, Parkinson’s, and rare neurological diseases. As a dedicated Neurology CRO, we help move your program from Phase I to market faster and more efficiently. Whether you need a bioequivalence CRO Europe for generics or a strategic partner for first-in-human gene therapy studies – explore our experience and case studies on our website.
